RODMAN&RENSHAW upgraded shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports.
Several other equities analysts also recently issued reports on the stock. Maxim Group assumed coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They set a "buy" rating and a $15.00 price target for the company. Rodman & Renshaw began coverage on TuHURA Biosciences in a report on Thursday. They set a "buy" rating and a $11.00 target price on the stock.
Get Our Latest Stock Analysis on TuHURA Biosciences
TuHURA Biosciences Stock Performance
Shares of NASDAQ:HURA traded up $0.48 during midday trading on Thursday, hitting $4.48. 1,293,353 shares of the stock were exchanged, compared to its average volume of 296,950. TuHURA Biosciences has a 12 month low of $2.84 and a 12 month high of $14.60.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
